Astec LifeSciences Approves ₹249.35 Cr Rights Issue at ₹890/Share; Record Date Set for July 4
By Ankur Chandra | Published at: Jun 30, 2025 06:35 PM IST
Mumbai, June 30 — Astec LifeSciences Ltd (BSE: 533138, NSE: ASTEC) has approved a rights issue of equity shares aggregating up to ₹249.35 crore, offering shareholders an opportunity to subscribe at ₹890 per share. The move was finalized during the Board meeting held today.
Key Rights Issue Details
The rights issue comprises 28,01,673 fully paid-up equity shares at a price of ₹890 per share, which includes a premium of ₹880 per share. The face value of each share is ₹10.
| Particulars | Details |
|---|---|
| Issue Size | ₹249.35 crore |
| No. of Shares Offered | 28,01,673 equity shares |
| Issue Price | ₹890 per share |
| Face Value | ₹10 |
| Premium per Share | ₹880 |
| Record Date | July 4, 2025 |
| ISIN for Rights Entitlement | INE563J20010 |
| Rights Ratio | 1:7 (1 share for every 7 held) |
Timeline for the Rights Issue
| Event | Date |
|---|---|
| Issue Opening Date | July 14, 2025 (Monday) |
| Last Date for On-Market Renunciation | July 22, 2025 (Tuesday) |
| Issue Closing Date | July 28, 2025 (Monday)* |
*The Board retains the right to extend the closing date, subject to a maximum of 30 days from the opening date.
Post-issue, the company’s outstanding equity shares will increase from 1,96,11,710 to 2,24,13,383, assuming full subscription and payment of call monies.
Regulatory Compliance
This rights issue is undertaken in compliance with:
- Regulation 30 and 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.
- Applicable provisions of the Companies Act, 2013.
Application and Renunciation Process
Eligible shareholders will receive their rights entitlement (RE) in dematerialized form under the ISIN INE563J20010. REs can be:
- Subscribed directly via application, or
- Renounced (fully or partly) through on-market or off-market transfer.
REs not exercised before the closing date will lapse, and no equity shares will be allotted against such REs.
About the Company
Astec LifeSciences Ltd, part of the Godrej Group, is a listed agrochemical and pharmaceutical intermediate manufacturing company headquartered in Mumbai. The company’s equity shares are actively traded on both BSE and NSE.
REF: https://nsearchives.nseindia.com/corporate/ASTEC_30062025165330_BSENSEBMOUTCOME30062025.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
